Blocking certain signals during surgery to slow down ovarian cancer growth
Inhibiting beta-adrenergic and COX-2 signaling during the perioperative period to reduce ovarian cancer progression
This study is looking at whether certain medications can help women with ovarian cancer by reducing stress and inflammation around the time of their surgery, with the hope of improving their chances of living longer and keeping the cancer from getting worse.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Tel Aviv University NIH-funded |
| Lab location | 1 site (Tel Aviv, Israel) |
| Project ID | NIH-10937095 on NIH RePORTER |
What this research studies
This research investigates the effects of inhibiting beta-adrenergic and COX-2 signaling during the critical perioperative period, which is the time just before and after surgery. The study aims to explore how these interventions can reduce the growth and spread of ovarian cancer by addressing stress and inflammation that often occur during this time. By conducting a small clinical trial with women undergoing surgery for ovarian cancer, the researchers will assess the safety and effectiveness of using specific medications to potentially improve long-term survival rates and reduce cancer progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with ovarian cancer who are scheduled for surgery.
Not a fit: Patients with advanced ovarian cancer who are not undergoing surgery may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for slowing down ovarian cancer progression and improving survival rates for patients undergoing surgery.
How similar studies have performed: Previous small clinical trials have shown promising results with similar approaches in other types of cancer, indicating potential for success in this research.
Where this research is happening
Tel Aviv, Israel
- Tel Aviv University — Tel Aviv, Israel (Active)
Researchers
- Principal investigator: Ben-Eliyahu, Shamgar — Tel Aviv University
- Study coordinator: Ben-Eliyahu, Shamgar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.